Tech Company Financing Transactions
Verdiva Bio Funding Round
Verdiva Bio, operating out of London, secured $411 million from Forbion Capital Partners, General Atlantic and private investors.
Transaction Overview
Company Name
Announced On
1/10/2025
Transaction Type
Venture Equity
Amount
$411,000,000
Round
Series A
Investors
Forbion Capital Partners (Lead Investor) (Wouter Joustra)
General Atlantic (Lead Investor) (Brett Zbar)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
London, Undisclosed
UK
London, Undisclosed
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options to transform the lives of millions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Khurem Farooq
Browse more venture capital transactions:
Prev: 1/10/2025: SEED venture capital transaction
Next: 1/10/2025: Ouro Medicines venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs